ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,567.19
1.06%
US Tech 100
19,827.20
0.94%
Dow Jones
39,375.87
0.17%
Brent Oil
86.775
0.00%
Bitcoin
56,542.21
-0.19%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Altimmune Inc (ALT) Quote

Altimmune Inc

Altimmune Inc (ALT)

Analytica Limited
Altitude Group Plc
Alturas Minerals Corp
6.62
0.02
(0.30%)
Closed July 05 4:00PM
Delayed by 15 minutes
6.62
0.00
(0.00%)
After Hours: 7:59PM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
6.62
Bid
6.55
Ask
6.62
Volume
2,319,226
6.33 Day's Range 6.6799
2.09 52 Week Range 14.84
Market Cap
467.954M
Previous Close
6.60
Open
6.59
Last Trade
450
@
6.62
(formt)
Last Trade Time
Financial Volume
$ 15,031,248
VWAP
6.4811
Average Volume (3m)
3,627,636
Shares Outstanding
70,902,191
Dividend Yield
-
PE Ratio
-5.31
Earnings Per Share (EPS)
-1.25
Revenue
426k
Net Profit
-88.45M

About Altimmune Inc

Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the tre... Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH (non-alcoholic steatohepatitis). In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B virus (HBV). Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.altimmune.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Altimmune Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ALT. The last closing price for Altimmune was $6.60. Over the last year, Altimmune shares have traded in a share price range of $ 2.09 to $ 14.84.

Altimmune currently has 70,902,191 shares outstanding. The market capitalization of Altimmune is $467.95 million. Altimmune has a price to earnings ratio (PE ratio) of -5.31.

ALT Latest News

More News

Lost Money on Altimmune, Inc.(ALT)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm

Lost Money on Altimmune, Inc.(ALT)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm PR Newswire NEW YORK, July 3, 2024 NEW YORK, July 3, 2024 /PRNewswire/ -- The Gross Law...

July 03 2024
PR Newswire (US)

Altimmune to Participate at Leerink Partners Therapeutics Forum

GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Companyā€™s management team will...

July 02 2024
GlobeNewswire Inc.

Lost Money on Altimmune, Inc.(ALT)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm

Lost Money on Altimmune, Inc.(ALT)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm PR Newswire NEW YORK, June 28, 2024 NEW YORK, June 28, 2024 /PRNewswire/ -- The Gross Law...

June 28 2024
PR Newswire (US)

Altimmune Mourns Passing of Chief Financial Officer, Richard Eisenstadt

GAITHERSBURG, Md., June 26, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc.Ā (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Richard Eisenstadt, the Companyā€™s Chief...

June 26 2024
GlobeNewswire Inc.

Shareholders that lost money on Altimmune, Inc.(ALT) should contact The Gross Law Firm about pending Class Action - ALT

Shareholders that lost money on Altimmune, Inc.(ALT) should contact The Gross Law Firm about pending Class Action - ALT PR Newswire NEW YORK, June 25, 2024 NEW YORK, June 25, 2024 /PRNewswire/...

June 25 2024
PR Newswire (US)

Altimmune Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at the American Diabetes Associationā€™s 84th Scientific Sessions

GAITHERSBURG, Md., June 23, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc.Ā (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today presented data from the 48-week Phase 2 MOMENTUM clinical...

June 23 2024
GlobeNewswire Inc.

Altimmune Presents Data on the Effect of Pemvidutide on Cardioinflammatory Lipids during Oral Presentation at American Diabetes Associationā€™s 84th Annual Scientific Sessions

GAITHERSBURG, Md., June 22, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc.Ā (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today presented data on the effect of pemvidutide, its...

June 22 2024
GlobeNewswire Inc.

Altimmune to Participate in the Piper Sandler 2nd Annual Virtual Obesity Investor Day to Discuss ADA Takeaways

GAITHERSBURG, Md., June 20, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Companyā€™s management team will...

June 20 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.233.599374021916.397.476.340434036.80352559CS
40.223.43756.48.495.6453520806.6609111CS
12-1.71-20.52821128458.339.55.6436276367.06370601CS
26-5-43.029259896711.6214.845.6446337989.21524531CS
523.1490.22988505753.4814.842.0949433077.45059716CS
156-2.57-27.9651795439.1923.492.0926572948.49155229CS
2604.22175.8333333332.435.11.4522719719.97672641CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BENFBeneficient
$ 4.785
(122.56%)
46.45M
SHOTWSafety Shot Inc
$ 0.33
(83.33%)
1.6k
QLGNQualigen Therapeutics Inc
$ 0.28
(59.64%)
244.67M
INVZWInnoviz Technologies Ltd
$ 0.2499
(51.91%)
17.79k
ZAPPZapp Electric Vehicles Group Ltd
$ 4.06
(49.26%)
50.33M
VEVVicinity Motor Corporation
$ 0.391
(-30.67%)
409.44k
SKYESkye Bioscience Inc
$ 5.495
(-26.34%)
353.28k
CLEUChina Liberal Education Holdings Ltd
$ 2.16
(-24.74%)
13.4M
JZXNJiuzi Holdings Inc
$ 2.60
(-23.53%)
57.7k
WHLRWheeler Real Estate Investment Trust Inc
$ 15.02
(-23.01%)
30.35k
MAXNMaxeon Solar Technologies Ltd
$ 0.2378
(36.98%)
519.98M
QLGNQualigen Therapeutics Inc
$ 0.28
(59.64%)
244.67M
NVDANVIDIA Corporation
$ 125.83
(-1.91%)
214.16M
TSLATesla Inc
$ 251.52
(2.08%)
154.49M
SIRISirius XM Holdings Inc
$ 3.715
(5.24%)
121.14M

ALT Discussion

View Posts
Mark102 Mark102 4 days ago
Beautiful Bull Flag
šŸ‘ļø0
girlfriend girlfriend 1 week ago
Well....not quite but a nice pop anyways this week.
šŸ‘ļø0
Mark102 Mark102 2 weeks ago
Last chance next week above 20
šŸ‘ļø0
Mark102 Mark102 2 weeks ago
It's being shorted by its competitors not tutes. . An advisor from Lilly is making the presentations of pemvi data this weekend.its what you know not what some want you to believe.
šŸ‘ļø0
brfv11 brfv11 3 weeks ago
Not a chance at 60. Shorts are playing this one perfectly. Investors are just not interested in ALT. Good luck.
šŸ‘ļø0
Mark102 Mark102 3 weeks ago
Shorts looking weak and vulnerable today any trading room with the funds could squeeze this to 60 easy
šŸ‘ļø0
Mark102 Mark102 3 weeks ago
Goldman Sachs been short stacking here for months and they are hosting the fireside tomorrow. I'm loading up today
šŸ‘ļø0
brfv11 brfv11 4 weeks ago
Time to admit shorty got this one right! This one is going all the way down.
Merger/ buyout what a joke.
šŸ‘ļø0
akamaii akamaii 1 month ago
This Wednesday we hope data rules. Give us data 📈
šŸ‘ļø0
akamaii akamaii 2 months ago
Going long for a year 75 target or 50 plus
šŸ‘ļø0
Mt. Blanc Mt. Blanc 3 months ago
So much for my ALT prediction.

The stock slipped to $7 and may be cratering more since it's getting no love.

Maybe ALT is a $5 stock or lower if buyers aren't interested.

mb
šŸ‘ļø0
Mt. Blanc Mt. Blanc 3 months ago
Radar. ALT $11- $12

Getting picked up.

mb
šŸ‘ļø0
Monksdream Monksdream 3 months ago
ALT over $10
Next day settlement begins 5/28 per SEC mandate
šŸ‘ļø0
Monksdream Monksdream 3 months ago
ALT 10Q due 3/27
Next day settlement begins 5/28
šŸ‘ļø0
saigai saigai 4 months ago
patiently waiting.. for sure something in the way of news is right there and it can only be a plus.. i want the buyout.. let say 4 billion.. 80 bucks a share..gl
šŸ‘ļø0
Mark102 Mark102 4 months ago
Buyout? Partnership? In less than 9 trading days we will find out.
šŸ‘ļø0
Mark102 Mark102 4 months ago
BUCKLE UP. going to break 15 soon
šŸ‘ļø0
saigai saigai 4 months ago
a good read
https://www.rcplondon.ac.uk/news/world-obesity-day-let-s-talk-about-drugs
šŸ‘ļø0
saigai saigai 4 months ago
slow and steady is healthy as the data goes as well.. fast weight loss is never good and the deeper dive into the data im sure will find that Alt has a wider profile a safer profile as it relates to muscle loss and bone density. time will tell...in any case the real value here is the undiscovered uses.. wide profile more mkts...long and strong ...
šŸ‘ļø0
Mt. Blanc Mt. Blanc 4 months ago
ALT @ $12?

Interesting

mb
šŸ‘ļø0
saigai saigai 4 months ago
institutional ownership from nasdaq site
https://www.nasdaq.com/market-activity/stocks/alt/institutional-holdings
šŸ‘ļø0
saigai saigai 5 months ago
big volume wrong direction for now
šŸ‘ļø0
saigai saigai 5 months ago
a good read
https://finance.yahoo.com/news/weight-loss-drugs-patients-lose-134837816.html
šŸ‘ļø0
saigai saigai 5 months ago
and a few more...
šŸ‘ļø0
saigai saigai 5 months ago
you wont be able to chase this..you either in before the news or outside looking in.. patience of a saint..
šŸ‘ļø0
saigai saigai 6 months ago
driving me nutz but i wont sell this until !!!
šŸ‘ļø0
murocman murocman 6 months ago
Post from another board relevant to ALT:

GLP-1 drugs will_be supply-constrained for_a_few_years, according to the NVO and LLY webcasts at JPM. All in-house and CMO capacity suitable for manufacturing injected GLP-1 drugs is already in service. Moreover, the eventual uptake of oral GLP-1 drugs will not ease the manufacturing bottleneck as much as people might think because the low bioavailability of the oral agents requires large amounts of API.
šŸ‘ļø0
AGORDON AGORDON 6 months ago
Altimmune, Inc.
(Nasdaq - ALT) $12/share
Market cap = $644M
Cash = $140M
Cash Burn rate = ($76)/Y
Catalysts:
Pemvidutide - Weight loss drug. Peptide based GLP-1/Glucagon dual receptor agonist. Phase 2 results were respectable. At 48 weeks, for 2.4mg (high dose), weight loss of -15.6% (on the low end of the expected 15-20%)., but comparable to Mounjaro. The TRAEs appear to be less than Mounjaro's. The drug did reduce triglycerides.
HepTCell - an immunotherapeutic for Chronic Hepatitis B. In Phase 2 trials. Next read out could be in April, 2024.
šŸ‘ļø0
Mark102 Mark102 6 months ago
I was wrong ALT is attending the JPM Let's get this deal done.
šŸ‘ļø0
saigai saigai 6 months ago
thanks a lot.. im on a new computer.. id rather have oral surgery than learn a new computer
šŸ‘ļø0
Mark102 Mark102 6 months ago
Data is in check Twitter. Weight loss is a 100 billion market. The results on the liver data show a 100 % reduction of fat at the highest dose. That's a 40 billion market.
Now why is ALT not attending the JPM conference this week? Stay tuned
šŸ‘ļø0
saigai saigai 6 months ago
im hanging around bewteen the two potential mkts for their drug its too crazy to even think out loud lets see what the data says.. if its good or really good. all hell will break out
šŸ‘ļø0
Mark102 Mark102 6 months ago
Float is locked, tutes trying to shake few out but this is a done deal IMO
šŸ‘ļø0
saigai saigai 6 months ago
this is a powder keg...
šŸ‘ļø0
saigai saigai 6 months ago
i believe if they wanted to they could have closed a deal by now but they wait till after the new data.. i wonder why.. there is no way for this to go but way up from here..glta
šŸ‘ļø0
Mark102 Mark102 6 months ago
Been Holding since 6. Buyout or partnership is imminent.
šŸ‘ļø0
1hot toddy 1hot toddy 6 months ago
HUGE BUYS NOW 10K BUY $100K BUY $$$$$$$$$$$$$$$$$$
šŸ‘ļø0
Bud-Wiser Bud-Wiser 6 months ago
Nice comeback today -Iā€™m back in
šŸ‘ļø0
1hot toddy 1hot toddy 6 months ago
WOOOOOOOOOOOW 10K AND 9100 SHARE BUYS 2-$100,000 BUYS $$$$$$$$$$$$$$$$$$$$$$$$$$$$$
BABY MONSTER HERE
šŸ‘ļø0
eyeownu eyeownu 6 months ago
got dammmmmmmmmmm. oprah must be buying out the company
šŸ‘ļø0
1hot toddy 1hot toddy 6 months ago
WOOOOOOW 10,000 SHARE BUY $110,000 BUY $$$$$$$$$$$$$$$$
MONSTER WEIGHT LOSS CO HERE
šŸ‘ļø0
Mark102 Mark102 6 months ago
Next Gap to 19 to fill. PT 60 to 100 on a buyout
šŸ‘ļø0
1hot toddy 1hot toddy 7 months ago
WOOOOOOOOOOOW 21000 SHARE BUY OVER $150,000 BUY . KILLER WEIGHT LOSS HERE $$$$$$$$$$$
šŸ‘ļø0
eyeownu eyeownu 7 months ago
rallys over IMO. end of year.. could be wrong tho!
šŸ‘ļø0
1hot toddy 1hot toddy 7 months ago
WOOOOOOOOOOW 11000 SHARE BUY $90000 BUY WEIGHT LOSS RESULTS GREAT $$$$$
šŸ‘ļø0
1hot toddy 1hot toddy 7 months ago
HUGE BUYS 8000 SHARES PLUS BUNCH OF 4000 SHARE BUYS $$$$$$$$$
šŸ‘ļø0
1hot toddy 1hot toddy 7 months ago
WOOOOOOOW 8800 SHARE BUY $60000 BUY $$$$$$$$$4
šŸ‘ļø0
saigai saigai 7 months ago
volume still there
šŸ‘ļø0
1hot toddy 1hot toddy 7 months ago
25000 share buy plus 10k buy $$$$$$$$$$$$$$
šŸ‘ļø0
saigai saigai 7 months ago
what a day tomorrow even better
šŸ‘ļø0

Your Recent History

NASDAQ
ALT
Altimmune
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved